Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11922573 | 0.82 | CFTR (0.51) | TDP1FPR2SCN9ADRD1ATM | |
| SCHEMBL12303690 | 0.80 | TDP1 (0.49) | TDP1FPR2SCN9ADRD1ATM | |
| SCHEMBL12303705 | 0.78 | MAPK10 (0.45) | TDP1P2RY1 | |
| SCHEMBL12763926 | 0.77 | TDP1 (0.44) | TDP1FPR2SCN9ADRD1KCNH2 | |
| SCHEMBL11922574 | 0.77 | TDP1 (0.50) | TDP1FPR2SCN9ADRD1KMT2A | |
| SCHEMBL11922572 | 0.77 | FPR2 (0.48) | TDP1FPR2SCN9ADRD1ATM | |
| SCHEMBL11991464 | 0.76 | SCN9A (0.45) | TDP1FPR2SCN9ADRD1KCNH2 | |
| SCHEMBL12819938 | 0.75 | P2RY1 (0.46) | TDP1DRD1P2RY1 | |
| SCHEMBL11992930 | 0.75 | SCN9A (0.45) | TDP1FPR2SCN9ADRD1KCNH2 | |
| SCHEMBL4318737 | 0.75 | LMNA (0.53) | TDP1FPR2SCN9AATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | TDP1 1792/4885FPR2 2994/4885SCN9A 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.